AU2496199A - Copolymer compositions for oral delivery - Google Patents

Copolymer compositions for oral delivery

Info

Publication number
AU2496199A
AU2496199A AU24961/99A AU2496199A AU2496199A AU 2496199 A AU2496199 A AU 2496199A AU 24961/99 A AU24961/99 A AU 24961/99A AU 2496199 A AU2496199 A AU 2496199A AU 2496199 A AU2496199 A AU 2496199A
Authority
AU
Australia
Prior art keywords
oral delivery
copolymer compositions
compositions
poly
oxypropylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24961/99A
Other languages
English (en)
Inventor
Valery Y. Alakov
Elena V. Batrakova
Alexander V Kabanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supratek Pharma Inc
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Publication of AU2496199A publication Critical patent/AU2496199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU24961/99A 1998-02-06 1999-02-05 Copolymer compositions for oral delivery Abandoned AU2496199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/019,648 US6277410B1 (en) 1992-10-08 1998-02-06 Copolymer compositions for oral delivery
US09019648 1998-02-06
PCT/US1999/002538 WO1999039731A1 (en) 1998-02-06 1999-02-05 Copolymer compositions for oral delivery

Publications (1)

Publication Number Publication Date
AU2496199A true AU2496199A (en) 1999-08-23

Family

ID=21794304

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24961/99A Abandoned AU2496199A (en) 1998-02-06 1999-02-05 Copolymer compositions for oral delivery

Country Status (8)

Country Link
US (2) US6277410B1 (enExample)
EP (1) EP1053010B1 (enExample)
JP (1) JP4685237B2 (enExample)
AT (1) ATE426397T1 (enExample)
AU (1) AU2496199A (enExample)
CA (1) CA2319057C (enExample)
DE (1) DE69940635D1 (enExample)
WO (1) WO1999039731A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
EP1563850A3 (en) * 2000-02-23 2008-02-20 Pfizer Products Inc. Method of increasing the bioavailability and tissue penetration of azithromycin
WO2001083698A2 (en) * 2000-04-28 2001-11-08 Supratek Pharma, Inc. Compositions and methods for inducing activation of dendritic cells
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
EP1289542B1 (en) * 2000-05-26 2008-07-16 Frohwitter, Bernhard Means for maintenance and/or correction of glucose concentration in blood
AU2002254342A1 (en) * 2001-03-23 2002-10-08 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
GB0131112D0 (en) * 2001-12-31 2002-02-13 Univ London Pharmacy Block copolymers
US20040220283A1 (en) * 2002-07-29 2004-11-04 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
AU2003261274C1 (en) * 2002-07-29 2009-02-12 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
DK1551876T3 (da) 2002-10-16 2011-06-14 Purdue Pharma Lp Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
US7422875B2 (en) 2004-07-20 2008-09-09 Board Of Regents Of The University Of Nebraska Compositions and methods for increasing protein production
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
WO2006099175A2 (en) * 2005-03-11 2006-09-21 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
TW200735770A (en) * 2006-01-10 2007-10-01 Innovaform Technologies Llc Pesticide delivery system
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
RU2409363C9 (ru) 2009-09-18 2013-12-10 Всеволод Иванович Киселев Фармацевтические композиции для пероральной доставки дииндолилметана (dim) и способы применения этих композиций
US8946301B2 (en) 2011-11-29 2015-02-03 Als Therapy Development Institute Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis
US8912215B2 (en) * 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
US20240024354A1 (en) * 2020-09-04 2024-01-25 The University Of Chicago Materials and methods of treating viral infection with amphiphilic block copolymers
EP4522183A2 (en) 2022-05-11 2025-03-19 Celgene Corporation Methods and uses related to t cell therapy and production of same

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027013A (en) 1976-01-22 1977-05-31 William L. Wilson Clottable fibrinogen free factor VIII and albumin product and process
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4106474A (en) 1977-03-17 1978-08-15 Modine Manufacturing Company Heat conserving space heater
US4865835A (en) 1982-06-02 1989-09-12 Begent Richard H J Diagnosis and treatment of tumors
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
ES8601706A1 (es) * 1983-05-16 1985-11-16 Merck & Co Inc Una composicion farmaceutica
US4485457A (en) 1983-05-31 1984-11-27 Cbs Inc. Memory system including RAM and page switchable ROM
US4772466A (en) 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
JPS61103836A (ja) 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
AU596986B2 (en) * 1985-06-18 1990-05-24 Emory University Biologically-active copolymers
US5114708A (en) 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
US5494660A (en) 1985-06-18 1996-02-27 Emory University Method for inhibiting microbial binding to surfaces
US5466445A (en) 1985-06-18 1995-11-14 Emory University Methods for reducing salmonella in chickens
US5183687A (en) 1985-06-18 1993-02-02 Emory University Method of treating poultry for coccidiosis
US5234683A (en) 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
JPS6270319A (ja) * 1985-07-30 1987-03-31 インタ−ナシヨナル・ミネラルズ・アンド・ケミカル・コ−ポレイシヨン 成長促進ホルモンの安定化
US5071649A (en) 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5032394A (en) 1986-05-15 1991-07-16 Emory University Method of treating burns
US5182106A (en) 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5240702A (en) 1986-05-15 1993-08-31 Emory University Method of treating stroke
US5041288A (en) 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5039520A (en) 1986-05-15 1991-08-13 Emory University Plasma extender
US4937070A (en) 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4873083A (en) 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US4997644A (en) 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US5250294A (en) 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US5028599A (en) 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US4897263A (en) 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5080894A (en) 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US4837014A (en) 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5089260A (en) 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US5030448A (en) 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5240701A (en) 1986-05-15 1993-08-31 Emory University Method of performing angioplasty procedures
US4801452A (en) 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US4879109A (en) 1986-05-15 1989-11-07 Emory University Method for treating burns
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5064643A (en) 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US5078995A (en) 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5198211A (en) 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US5017370A (en) 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5152979A (en) 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US5047236A (en) 1986-05-15 1991-09-10 Emory University Method of treating stroke
US4882168A (en) 1986-09-05 1989-11-21 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
DE3750176T2 (de) * 1986-09-22 1994-10-13 Emory University, Atlanta, Ga. Impfstoff und verfahren zur herstellung.
US5567859A (en) * 1991-03-19 1996-10-22 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
AU1396588A (en) * 1987-02-20 1988-09-14 Emory University Antiinfective compounds and method of use
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
CA1335879C (en) 1987-07-27 1995-06-13 Bruce Andrew Cornell Receptor membranes
US4853228A (en) 1987-07-28 1989-08-01 Micro-Pak, Inc. Method of manufacturing unilamellar lipid vesicles
IE911403A1 (en) * 1990-04-26 1991-11-06 Cytrx Corp Compositions and method for topical treatment of damaged or¹diseased tissue
NZ238731A (en) * 1990-06-27 1996-02-27 Univ Emory Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DE69230372T2 (de) * 1991-03-19 2000-06-15 Cytrx Corp., Norcross Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5622649A (en) 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
CA2120359C (en) 1991-10-04 2000-12-26 Tomas Landh Particles, method of preparing said particles and uses thereof
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
US5470568A (en) 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
US5840319A (en) 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
ATE198268T1 (de) 1992-10-08 2001-01-15 Supratek Pharma Inc Zusammensetzung von in mizellen eingeschlossenen antineoplastischen wirkstoffen
US6153193A (en) 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US5488034A (en) 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
IL106578A (en) 1993-08-03 2000-08-13 Yissum Res Dev Co Pharmaceutical compositions for drug targeting
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5401296A (en) 1994-06-28 1995-03-28 Martenson; Irvin Precious metal extraction process
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
JP4117922B2 (ja) * 1996-03-28 2008-07-16 武田薬品工業株式会社 徐放性製剤およびその製造法

Also Published As

Publication number Publication date
DE69940635D1 (de) 2009-05-07
WO1999039731A1 (en) 1999-08-12
ATE426397T1 (de) 2009-04-15
US6277410B1 (en) 2001-08-21
EP1053010A1 (en) 2000-11-22
EP1053010A4 (en) 2002-08-21
CA2319057A1 (en) 1999-08-12
US6387406B1 (en) 2002-05-14
JP4685237B2 (ja) 2011-05-18
JP2002502825A (ja) 2002-01-29
CA2319057C (en) 2010-05-04
EP1053010B1 (en) 2009-03-25

Similar Documents

Publication Publication Date Title
AU2496199A (en) Copolymer compositions for oral delivery
TR200100054T2 (tr) Paroksetin metansülfonat
DE69905170D1 (en) Thiazolopyrimidinderivate
WO1996040055A3 (en) Biological agent compositions
DE69835201D1 (en) Neoglycoproteine
GC0000107A (en) Water - soluble pharmaceutical compositions in an ionic complex an the use thereof.
MXPA03007591A (es) Composiciones y metodos para mejorar el suministro de farmacos a traves de y a tejidos epiteliales.
WO1995021601A3 (en) Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
BR9916857A (pt) 4 heteroaril diarilaminas
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
MXPA03009772A (es) Metodos y composiciones para tratar lesiones orales y del esofago.
IL140710A0 (en) Pulmonary delivery of active agents
TR200100366T2 (tr) Aktif madde dağıtmaya mahsus bileşikler ve bileşimler.
ATE291926T1 (de) Im wesentlichen ölfreie cyclosporin zusammensetzungen
ZA200007299B (en) Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol.
GB9717905D0 (en) Lipid-containing compositions and uses thereof
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
YU13301A (sh) Muskarinski agonisti i antagonisti
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
EP1558282A4 (en) COMPOSITIONS AGAINST CANCER AND INFECTION DISEASES AND METHOD OF USE THEREOF
EP0916670A3 (en) Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists
WO2002046225A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
AU2821200A (en) Matrix protein compositions for grafting
GB9811221D0 (en) Bacterial-pheromones and uses therefor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase